Amarin Corp Plc (AMRN)

[rosemountbomber]

STS, you have a valid point following that line of thinking. What I find difficult is one fellow (Nissen) states that the increases were large whereas another fellow (Dr. Bhatt), says that the increases were small from an absolute view and that they only look larger from a relative point of view. And that from a very low baseline. How do you mesh those two descriptions?

But I guess there is a reason that the FDA does not approve CVD drugs based on biomarkers. It might approve drugs to alter biomarkers but they aren't going to make any claims about CVD.

At one point the MO discussion was about MO interfering with statin absorption. But if the subjects took the statin at different time then that would be rather unlikely. So now we fall back to wondering whether MO on its own can raise these biomarkers.

Jury may be out for awhile (or at least before everyone agrees), and as an example, it has been decades that the debate has been going on concerning saturated fat, and we still see data that contradicts the prevailing (mostly) view:

https://www.frontiersin.org/articles/10.3389/fnut.2021.748847/full

Actually, just saw this and it is a bit funny: